You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

CLINICAL TRIALS PROFILE FOR NALBUPHINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Nalbuphine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00155233 ↗ Interaction Between Nalbuphine and Morphine in PCA Unknown status National Taiwan University Hospital Phase 4 2005-01-01 1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine
NCT00200564 ↗ Ketamine and Postoperative Analgesia in Children Unknown status Nantes University Hospital Phase 4 2004-02-01 The benefit of small doses of ketamine has been demonstrated for postoperative analgesia in adults but remains unproved in children. The investigators' purpose is to evaluate the effects of continuous intravenous small doses of ketamine versus placebo to improve the quality of postoperative analgesia in children (6 months to 6 years of age). Caudal anesthesia is performed for intraoperative analgesia and all children receive paracetamol, a non-steroidal anti-inflammatory and continuous intravenous nalbuphine.
NCT00323154 ↗ Nalbuphine for the Treatment of Opioid Induced Pruritus in Children Completed University of British Columbia Phase 3 2004-03-01 Itching is a frequent and disturbing side effect of the use of pain medication such as morphine. In the post-operative period, it can be more distressing to pediatric patients than their pain. The current first line treatment, an antihistamine (Benadryl), has a low efficacy. This treatment causes sleepiness and may be dangerous when used in combination with other drugs. Nalbuphine has analgesic properties similar to morphine as well as the ability to reverse some morphine-induced side effects, such as respiratory depression and itching. Nalbuphine has been used effectively for patients undergoing Caesarean sections. However, the effectiveness of nalbuphine in the pediatric population has not been investigated. We want to determine the efficacy of nalbuphine in the treatment of itching after morphine for postoperative pain relief. We will use a novel method to measure the effect of the treatment using an intensity scale before and after the drug, to determine the intensity difference.
NCT00499746 ↗ The Discriminative Effects of Tramadol in Humans Completed National Institute on Drug Abuse (NIDA) Phase 1/Phase 2 2007-11-01 This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.
NCT00707824 ↗ Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus Completed Mahidol University Phase 4 2000-06-01 Can epidural nalbuphine reduce incidence or severity of epidural morphine induced pruritus in patient undergoing cesarean section?
NCT00716807 ↗ Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain Terminated University of California, San Francisco N/A 2008-01-01 Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half.
NCT00874172 ↗ Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy Completed Assistance Publique - Hôpitaux de Paris N/A 2009-10-01 Quality of life of adult patients with sickle cell disease is deeply impaired by severe adverse medical events that inadvertently occur throughout their time life. Indeed, patients not presenting a life threatening condition often present to the emergency department with sickle cell disease crisis related pain. Currently, the effectiveness of specific analgesic strategies for treating sickle cell disease crisis related pain are mostly based on acetaminophen and opioid derivates combination along with oxygen delivery. Those strategies are effective but may last up to half an hour to obtain pain relief. This delay mostly depends on the availability of venous access and on individual patient response to treatment. Nitrous oxide is a volatile efficient analgesic therapy that has been repeatedly shown to allow rapid analgesia in the emergency department setting. The investigators hypothesise that a new analgesic strategy (rapid optimized analgesic strategy) including nitrous oxide and nefopam would be as safe and more rapidly effective than current analgesic strategy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nalbuphine Hydrochloride

Condition Name

Condition Name for Nalbuphine Hydrochloride
Intervention Trials
Pain, Postoperative 10
Postoperative Pain 10
Pain 6
Anesthesia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nalbuphine Hydrochloride
Intervention Trials
Pain, Postoperative 33
Pruritus 9
Vomiting 6
Emergence Delirium 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nalbuphine Hydrochloride

Trials by Country

Trials by Country for Nalbuphine Hydrochloride
Location Trials
United States 86
Egypt 32
China 22
Taiwan 14
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nalbuphine Hydrochloride
Location Trials
California 7
Ohio 5
Texas 4
Pennsylvania 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nalbuphine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Nalbuphine Hydrochloride
Clinical Trial Phase Trials
Phase 4 30
Phase 3 8
Phase 2/Phase 3 10
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nalbuphine Hydrochloride
Clinical Trial Phase Trials
Completed 46
Recruiting 19
Not yet recruiting 16
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nalbuphine Hydrochloride

Sponsor Name

Sponsor Name for Nalbuphine Hydrochloride
Sponsor Trials
Assiut University 14
Trevi Therapeutics 9
Ain Shams University 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nalbuphine Hydrochloride
Sponsor Trials
Other 101
Industry 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.